National Institute on Drug Abuse; Notice of Meeting, 19893-19894 [2021-07712]
Download as PDF
<![CDATA[
19893
Federal Register / Vol. 86, No. 71 / Thursday, April 15, 2021 / Notices
ANNUAL BURDEN ESTIMATES
Instrument
Respondents
Site Visit 1 Interview Guide for Administrators.
Child Welfare Agency Administrators
Licensed LifeSet Experts.
Provider Agency Administrators.
LifeSet Developer Administrators.
Child Welfare Agency Administrators
Licensed LifeSet Experts.
Provider Agency Administrators.
LifeSet Developer Administrators.
LifeSet Specialists ...............................
LifeSet Team Supervisors.
Youth Formerly in Foster Care ...........
Agency and Program Staff .................
Site Visit 2 Interview Guide for Administrators.
Site Visit 2 Focus Group Guide for
Staff.
Baseline Youth Survey ........................
Administrative data file ........................
Estimated Total Annual Burden
Hours: 160.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Authority: 42 U.S.C. 677.
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2021–07688 Filed 4–14–21; 8:45 am]
BILLING CODE 4184–25–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Number of
responses per
respondent
(total over
request
period)
Number of
respondents
(total over
request
period)
National Institute on Drug Abuse;
Notice of Closed Meeting
jbell on DSKJLSW7X2PROD with NOTICES
VerDate Sep<11>2014
17:35 Apr 14, 2021
Jkt 253001
1
22
7
22
1
1
22
7
12
1
1.5
18
6
600
12
1
1
0.6
5
360
60
120
20
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Leveraging Big Data Science to Elucidate the
Mechanisms of HIV Activity and Interaction
with Substance Use Disorder (R01, R21—
Clinical Trials Not Allowed).
Date: May 18, 2021.
Time: 12:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Ipolia R. Ramadan, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–4471, ramadanir@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
PO 00000
Frm 00025
Fmt 4703
Annual burden
(in hours)
1
[FR Doc. 2021–07708 Filed 4–14–21; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
Total burden
(in hours)
22
Dated: April 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
Avg. burden
per response
(in hours)
Sfmt 4703
meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual
meeting and is open to the public, as
indicated below. Individuals who plan
to view the virtual meeting and need
special assistance or other reasonable
accommodations to view the meeting,
should notify the Contact Person listed
below in advance of the meeting. The
open session will be videocast and can
be accessed from the NIH Videocasting
and Podcasting website (https://
videocast.nih.gov/).
A portion of this will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: May 11, 2021.
Closed: 11:00 a.m. to 12:15 p.m.
Agenda: To review and evaluate grant
applications.
Open: 12:45 p.m. to 4:30 p.m.
Agenda: Presentations and other business
of the Council.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Susan R.B. Weiss, Ph.D.,
Director, Division of Extramural Research,
Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North,
RM 09D08, 11601 Landsdown Street,
Bethesda, MD 20852, 301–443–6480, sweiss@
nida.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
E:\FR\FM\15APN1.SGM
15APN1
19894
Federal Register / Vol. 86, No. 71 / Thursday, April 15, 2021 / Notices
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: April 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–07712 Filed 4–14–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
jbell on DSKJLSW7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Gabriella Miller Kids First and
INCLUDE SEP.
Date: May 7, 2021.
Time: 11:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Suite 3100, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: National Human Genome
Research Institute, National Institutes of
Health, Barbara J. Thomas, Ph.D., Scientific
Review Officer, Scientific Review Branch,
6700B Rockledge Drive, Suite 3100,
Bethesda, MD 20892–6908, 301–402–8837,
barbara.thomas@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
VerDate Sep<11>2014
17:35 Apr 14, 2021
Jkt 253001
Dated: April 9, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–07711 Filed 4–14–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–2: NCI
Clinical and Translational Cancer Research.
Date: June 3–4, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W264, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Ombretta Salvucci, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W264, Rockville,
Maryland 20850, 240–276–7286, salvucco@
mail.nih.gov.
Name of Committee: National Cancer
Institute Initial Review Group; Subcommittee
F—Institutional Training and Education.
Date: June 8, 2021.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W234, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Adriana Stoica, Ph.D.,
Scientific Review Officer, Resources and
Training Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W234, Rockville, Maryland 20850,
240–276–6368, Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Program Project V (P01).
Date: June 10–11, 2021.
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W240, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Hasan Siddiqui, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W240, Rockville,
Maryland 20850, 240–276–5122,
hasan.siddiqui@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–9: NCI
Clinical and Translational Cancer Research.
Date: June 24, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W108, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Rockville, Maryland 20850, 240–276–6343,
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Research Specialist Award (R50).
Date: June 24–25, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W242, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Zhiqiang Zou, M.D., Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W242, Rockville,
Maryland 20850, 240–276–6372, zouzhiq@
mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Social and
Behavioral Intervention Research to Address
Modifiable Risk Factors for Cancer in Rural
Populations (R01).
Date: June 25, 2021.
Time: 10:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute at Shady
Grove, 9609 Medical Center Drive, Room
7W618, Rockville, Maryland 20850,
(Telephone Conference Call).
Contact Person: Mukesh Kumar, Ph.D.,
Scientific Review Officer, Research Program
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W618,
Rockville, Maryland 20850, 240–276–6611,
mukesh.kumar3@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI
Pathway to Independence Award for
Outstanding Early Stage Postdoctoral
Researchers (K99/R00).
E:\FR\FM\15APN1.SGM
15APN1
]]>Agencies
[Federal Register Volume 86, Number 71 (Thursday, April 15, 2021)]
[Notices]
[Pages 19893-19894]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-07712]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the National Advisory
Council on Drug Abuse.
The meeting will be held as a virtual meeting and is open to the
public, as indicated below. Individuals who plan to view the virtual
meeting and need special assistance or other reasonable accommodations
to view the meeting, should notify the Contact Person listed below in
advance of the meeting. The open session will be videocast and can be
accessed from the NIH Videocasting and Podcasting website (https://videocast.nih.gov/).
A portion of this will be closed to the public in accordance with
the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: May 11, 2021.
Closed: 11:00 a.m. to 12:15 p.m.
Agenda: To review and evaluate grant applications.
Open: 12:45 p.m. to 4:30 p.m.
Agenda: Presentations and other business of the Council.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of
Extramural Research, Office of the Director, National Institute on
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown
Street, Bethesda, MD 20852, 301-443-6480, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when
[[Page 19894]]
applicable, the business or professional affiliation of the
interested person.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: April 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-07712 Filed 4-14-21; 8:45 am]
BILLING CODE 4140-01-P
